AI Analysis
AI-generated analysis. Always verify with the original filing.
Adagene reported full year 2025 financial results with a reduced net loss of $17.6 million and cash runway into early 2028, alongside positive clinical data for muzastotug showing a 29% ORR in MSS CRC.
Key Takeaways
1Muzastotug showed a 29% confirmed ORR in 20 mg/kg cohorts and 19.4 months median OS in 10 mg/kg cohorts for MSS CRC.
2Cash and cash equivalents were $74.5 million as of December 31, 2025, with runway expected to extend into early 2028.
3Net loss decreased to $17.6 million for 2025 from $33.4 million in 2024, reflecting reduced R&D expenses and revenue recognition.
4Net revenue increased to $7.7 million in 2025 from $0.1 million in 2024 due to collaboration agreements with Sanofi and others.
5Randomized Phase 2 trial enrollment is ahead of plan, with results expected in 1H 2027.
6Safety profile maintained with 4% discontinuation rate and no Grade 4 or 5 TRAEs across 67 patients.